Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Autologous iNKT Cells with Regorafenib and PD-1 in Progressed HCC
NCT05962450Phase 2Recruiting
- Sponsor
- Beijing YouAn Hospital
- Start
- Oct 2023
- Primary completion
- Aug 2025
- Modality
- Cell Therapies
- Countries
- 1
01
Overview
Phase 2, randomised, open-label trial of autologous invariant natural killer T cells in hepatocellular carcinoma (HCC) (2 arms), sponsored by Beijing YouAn Hospital. Primary endpoint: Progression-Free Survival at 24 months. Started Oct 2023; status: recruiting.
02
Drugs
autologous invariant natural killer T cells
03
Conditions
hepatocellular carcinoma (HCC)
Beyond the preview
Go deeper on NCT05962450.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05962450.